← Eichor
Study identifier: NCT04939610 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

Condition: Solid Tumor  ·  Sponsor: Novartis Pharmaceuticals

PhasePhase 1/Phase 2
Planned participants222
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesenchymal origin, notably sarcoma and mesothelioma, FAP expression has also been observed on the tumor cells themselves. Given the restricted expression profile, FAP is a promising target for peptide-targeted radionuclide imaging and therapeutic agents. Phase 1 of this study is designed to evaluate the safety and establish the recommended intravenous (IV) Phase 2 dose (RP2D) for \[177Lu\]Lu FAP 2286 monotherapy in participants with FAP expressing solid tumors. Phase 2 is designed to evaluate the safety and efficacy of \[177Lu\]Lu FAP 2286 as monotherapy in participants with pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and breast cancer (BC) and in combination with chemotherapy in participants with untreated PDAC or relapsed NSCLC. Participants in both Phase 1 and 2 will be selected for treatment with \[177Lu\]Lu FAP 2286 based on \[68Ga\]Ga FAP 2286 imaging for determining tumor FAP expression.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals  ·  1-888-689-6682  ·  novartis.email@novartis.com

Novartis Pharmaceuticals  ·  +41613241111  ·  novartis.email@novartis.com

Always discuss trial participation with your own doctor first.

Locations (41)

UAB Comprehensive Cancer CenterBirmingham, Alabama, United StatesRecruiting
City of HopeDuarte, California, United StatesRecruiting
Hoag Hospital IrvineIrvine, California, United StatesRecruiting
University of California Los Angeles (UCLA)Los Angeles, California, United StatesRecruiting
UCSF Medical CenterSan Francisco, California, United StatesRecruiting
Mayo ClinicJacksonville, Florida, United StatesRecruiting
University of Miami Hospital and ClinicsMiami, Florida, United StatesRecruiting
University of Chicago Medical CenterChicago, Illinois, United StatesRecruiting
University of Iowa Hospitals and ClinicsIowa City, Iowa, United StatesRecruiting
Karmanos Cancer InstituteDetroit, Michigan, United StatesRecruiting
Mayo ClinicRochester, Minnesota, United StatesRecruiting
Saint Louis University HospitalSt Louis, Missouri, United StatesRecruiting

+ 29 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04939610